The skin biopsies on both regions revealed multiple wellformed noncaseating granulomas with mainly epithelioid histiocytes, lymphocytes, and multinucleated giant cells in the dermis (Fig. 1C) . No foreign material or microorganism was detected by polarization and special stain. Chest X-ray showed some small suspicious nodules over the left lower lung (Fig. 1D ). Cutaneous and pulmonary sarcoidosis was diagnosed. The patient's laboratory data were all within normal limits. The patient then received oral prednisolone (5w10 mg/day) and intralesional triamcinolone acetonide injection on involved areas. The skin lesions improved after 1 month of therapy, and the pulmonary lesions were diminished on the following chest X-ray as well.
IFN-a is an immunomodulator commonly used in hepatitis C virus infection. Various dermatologic adverse effects have been associated with IFN-a therapy, including allergic reactions, lupus erythematosus, alopecia, psoriasis, extensive inflammation of actinic keratoses, 5 and sarcoidosis. 1e4 IFNaeinduced cutaneous sarcoidosis can appear before or concurrent with other organ involvement, 2 but its diagnosis can be easy and timely because of its distinct clinical and histopathological presentation. The time of onset varies from several days after the beginning therapy to 24 months after completing therapy. 1 The hypotheses of traumainduced sarcoidosis under IFN-a use include: (1) repeated trauma of the skin, such as tattoos, surgical scars, and venipuncture sites may trigger the activity of dendritic cells and result in granulomas 3, 4 ; (2) IFN-a stimulates the Th1 type immune response, which leads to the formation of granulomas 1 ; (3) ribavirin is also able to stimulate Th1 lymphocytes by inhibiting Th2 response 2 ; and (4) the hepatitis C virus itself exaggerates the expression of endogenous IFN-a. 
